Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - ornipressin, quantity: 5 iu/ml - injection, solution - excipient ingredients: sodium acetate; glacial acetic acid; sodium chloride; water for injections - local administration: to induce ischaemia and haemostasis at the site of an operation in various types of surgery where bleeding is a problem plastic surgery: hair transplants, meloplasty, otoplasty, skin grafts, resection of tumours etc obstetrics/gynaecology: vaginal repair, vaginal hysterectomy, cone biopsy of cervix, episiotomy, myomectomy. ent surgery: tonsillectomy, submucous resection of septum, myringoplasty etc. other types of surgery: neurosurgery, orofacial surgery, surgery of head and neck, abdominal and rectal surgery, care of burns (excision of eschar).

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - suppository, compressed - excipient ingredients: purified talc; povidone; macrogol 6000; magnesium stearate - treatment of ulcerative procitis.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - mesalazine, quantity: 1000 mg - enema - excipient ingredients: disodium edetate; sodium acetate; purified water; sodium metabisulfite; hydrochloric acid - for the treatment of ulcerative proctosigmoiditis and/or treatment of left-sided ulcerative colitis.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 0.1 mg/ml (equivalent: desmopressin, qty 0.089 mg/ml) - spray, solution - excipient ingredients: dibasic sodium phosphate dihydrate; citric acid monohydrate; sodium chloride; purified water; benzalkonium chloride - diabetes insipidus:the treatment of adh-sensitive cranial diabetes insipidus, including treatment of post-hypophysectomy polydipsia and polyuria.,nocturnal enuresis: minirin nasal spray is indicated for the symptomatic treatment of primary nocturnal enuresis in patients who have normal ability to concentrate urine. minirin nasal spray should be used only in patients who are refractory to the enuresis alarm or in patients in whom enuresis alarm is contraindicated or inappropriate, and where the oral administration of desmopressin is not feasible.,renal concentrating capacity: by intranasal administration to adults and children as a diagnostic test to establish renal concentrating capacity.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - quinagolide hydrochloride -

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - quinagolide hydrochloride, quantity: 0.0819 mg (equivalent: quinagolide hydrochloride, qty 75 microgram) - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; hypromellose; maize starch; microcrystalline cellulose; lactose monohydrate - hyperprolactinaemia (idiopathic or originating from a prolactin- secreting pituitary microadenoma or macroadenoma) associated with its clinical manifestations such as galactorrhoea, oligomenorrhoea, amenorrhoea, infertility and reduced libido.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 15 microgram/ml (equivalent: desmopressin, qty 13.4 microgram/ml) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride - mild and moderate haemophillia a and von willebrand?s disease: by intravenous infusion only, for the increase of factor viii levels in patients undergoing dental or minor surgery. not to be used in type iib von willebrand?s disease since platelet aggregation may be induced.,bleeding in patients with platelet dysfunction: treatment of excessive bleeding in patients with congenital or acquired clinical conditions associated with platelet dysfunction which is characterised by a prolonged bleeding time except glanzmann?s thrombasthenia or platelet cyclo-oxygenase deficiency.,examples are patients with uraemia, congenital or drug induced platelet dysfunction and patients undergoing cardiac surgery with cardiopulmonary bypass for prosthetic valve replacement or aorto-coronary bypass grafting especially when it is complicated by platelet function defects sufficient to prolong bleeding time despite relatively normal platelet cover. desmopressin acetate offers no benefit as routine therapy in patients having an uncomp

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - desmopressin acetate, quantity: 4 microgram/ml (equivalent: desmopressin, qty 3.56 microgram/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - diabetes insipidus: the treatment of adh sensitive cranial diabetes insipidus, including treatment of post hypophysectomy polydipsia and polyuria.,renal concentrating capacity: by intramuscular administration to adults only, as a diagnostic test to establish renal concentrating capacity.,mild and moderate haemophillia a and von willebrand?s disease: by intravenous infusion only, for the increase of factor viii levels in patients undergoing dental or minor surgery. not to be used in type iib von willebrand?s disease since platelet aggregation may be induced.,bleeding in patients with platelet dysfunction: treatment of excessive bleeding in patients with congenital or acquired clinical conditions associated with platelet dysfunction which is characterised by a prolonged bleeding time except glanzmann?s thrombasthenia or platelet cyclo-oxygenase deficiency.,examples are patients with uraemia, congenital or drug induced platelet dysfunction and patients undergoing cardiac surgery with cardiopulmonary bypass for p

Irland - Englisch - HPRA (Health Products Regulatory Authority)

cambridge healthcare ireland limited - propamidine isetionate - eye drops, solution - 0.1 percent weight/volume - other antiinfectives; propamidine

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - posaconazole, quantity: 100 mg - tablet, modified release - excipient ingredients: colloidal anhydrous silica; triethyl citrate; microcrystalline cellulose; croscarmellose sodium; propyl gallate; methacrylic acid - ethyl acrylate copolymer (1:1); xylitol; sodium stearylfumarate; hyprolose; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - posaconazole juno is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older:,? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy.,? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole juno is also indicated for the prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.